Reddit Posts
BIEL initiating study/clinical trial to treat Osteoarthritis
Mentions
BIEL . The CEO has hinted at promising news in the new year. It has been on the IHUB breakout board for the last few months .
In case anyone's feeling spicy, these are some penny babies I'm in (mostly scalping/re-entering) that I haven't heard much about: AIBT GTVH BIEL HYSR INVU PHBI NUMIF SNTX Not financial advice, obviously.
Your post with title "What do you guys think about stock BIEL?" has been automatically removed from r/PennyStocks for being low-effort/spam. (Low word count) probably by u/automod *I am a bot, and this action was performed automatically. Please [contact the moderators of this subreddit](/message/compose/?to=/r/pennystocks) if you have any questions or concerns.*
BIEL is a biomed company that makes a wearable pain management device. I have shares because this device works. I am using one right now.
Get that BIEL and double your money from the .0002 to .0004 runs 😅
Can we all please move on to BIEL. I have 130,000 shares if it goes to .35 I get my new TESLA. WallStreet mob can move this rocket to the launch pad and give everyone a thankful Turkey day !!!
Someone looking for sub pennies to invest in look at CBDD and BIEL.
Well they do not receive an audit and have a going concern disclosure. Their current ratio screams liquidity crisis. They also do not care about share holders, they have over 24 billion shares outstanding and issued nearly 1 billion just in the last year to stay afloat. [https://www.bielcorp.com/biel/wp-content/uploads/2022/04/BioElectronics-BIEL-OTC-Financials-31December2021.pdf](https://www.bielcorp.com/biel/wp-content/uploads/2022/04/BioElectronics-BIEL-OTC-Financials-31December2021.pdf) They also outsource their CFO position and management barely holds any equity (only 137 million shares worth .0011 a share. They obviously aren’t bullish if they aren’t accumulating. [https://www.bielcorp.com/biel/wp-content/uploads/2022/04/BIEL-Annual-2021-Disclosure-Statement\_Updated.pdf](https://www.bielcorp.com/biel/wp-content/uploads/2022/04/BIEL-Annual-2021-Disclosure-Statement_Updated.pdf)
BIEL, pharmaceutical company majoring in pain relief. Get crap from my buddies for years now. I just let it sit there, all XXXXX shares. My time will come. (Wringing hands) lol
BIEL is one that I own and even though I’m down it’s the one penny in my portfolio that I believe has the greatest chance of making me a millionaire. Not pumping, just sayin…. Quick summary: They have an actual product PEMF (Pulsed Electro-Magnetic Field) device that you can purchase right now at CVS, Amazon (4/5 stars 522 reviews), Target, Walmart, Walgreens…SOLD in nearly every country in the world! Q3 2021 - 1st profitable quarter in history reported. Unheard of in penny land!
New Update for Biel!!! BioElectronics Corporation Chairman Richard Staelin, Ph.D., Updates Company Achievements FREDERICK, MARYLAND, Feb. 28, 2022 -- (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL is pleased to update, in a letter from its Chairman, Richard Staelin, Ph.D., new distribution partners, personnel changes, and new clinical research studies. SALES UPDATE: BioElectronics Corporation is pleased to announce that it has signed two additional international distribution partners and received a new order from its longtime distribution partner in Bangladesh, Multiple Health Pharma, Ltd., who has resumed operations following shutdowns due to Covid. These two new international orders and the renewal order total in excess of $200,000.00. The first new order comes from Stada MENA DWC-LLC. It will be distributing ActiPatch in Bahrain and the Kingdom of Saudi Arabia. Erin Sanders, International Sales Manager for BioElectronics, said, “After lengthy negotiations and delays due to Covid, I am pleased to close the contract and bring on this well qualified and capable distribution partner.” Ms. Sanders has also finalized a contract with Modern Development Medical Company., which will be distributing both RecoveryRx and ActiPatch in Kuwait, Qatar, and Oman. In the United Arab Emirates, they will be focusing on the RecoveryRx brand. PERSONNEL UPDATE: The Company recently promoted Iqra “Ikki” Anwar-Dean to Director of Operations in recognition of her outstanding past performance. Ms. Anwar-Dean joined BioElectronics as a Marketing Manager in 2016 and earned her MBA from the University of Maryland while working full time. In her new role, Ikki will oversee all product production schedules, manage the inventory, and ensure that orders are filled and shipped expeditiously in addition to assisting with marketing. Additionally, the Company has hired Ms. Zoya Atiq as a Medical Device Compliance Engineer. Ms. Atiq earned a Bachelor of Science in Biomedical Engineering from the University of Buffalo, The State University of New York. In her most recent position, she spearheaded a traditional PreMarket Notification 510(k) submission to the FDA for a novel gastrointestinal tube. In her role at BioElectronics, Zoya will be primarily responsible for maintaining the Company’s regulatory/quality compliance with medical device industry standards and regulations. (ie ISO-13485, MDSAP, FDA QSR, 14971). She will also be responsible for writing technical and clinical documents as needed related to the Company’s technology and future clinical trials. We are excited to have Zoya join our Company. We fully expect that she will hit the ground running and quickly become an integral part of our team. CLINICAL RESEARCH UPDATE: In keeping with our emphasis on enhancing our core capability in PWST technology, we have initiated three new studies under the overall supervision of Drs. Ken Mcleod and Richard Staelin. The first is with a research group out of Stanford Medical Center which is studying carpal-metacarpal joint osteoarthritis (thumb arthritics) using our medical device. This 4-week study is using a randomized control trial (RCT) design on 120 patients. Publication of the results are planned after completion of the trial. A second RCT study is being conducted in the United Kingdom on 70 dogs with the goal of reducing the animals’ arthritis pain and increasing functionality. The study is ongoing and should be completed in the next few months. In addition to a new application and potential market for our device, we also are exploring a modified design of the product that has the potential to increase the power of the magnetic field deeper into the body. This study is part of the investigator’s PhD thesis. A third study is currently being conducted by researchers at a major surgical center that specializes in total knee (TKA) replacement. This retrospective study design compares 180 TKA patients who used our medical device with a matched sample who did not. The primary measures are narcotic use, functionality, and the advent of chronic pain after 90 days. The final draft of the paper is planned for mid-summer of 2022. Finally, the Company is in discussions with three other research teams, two interested in studying wound care and the third studying pain reduction. This third study, which is out of University of California, San Diego medical center is already in the pilot stage and is looking at refractory phantom pain and total hip and knee pain. Such studies will continue to facilitate the Company’s goal of finding new applications and markets for its PSwT technology by highlighting the efficacy and safety of these applications via high quality studies that can be published in peer review medical journals. Richard Staelin, Ph.D. Chairman of the Board About BioElectronics: BioElectronics Corporation is a leader in non-invasive electroceuticals and the manufacturer of industry leading disposable, drug-free, pain therapy devices for the over-the-counter treatment of back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative pain and wound care. For more information, visit www.bielcorp.com Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this email are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. Contact: Paul Knopick pknopick@eandecommunications.com 949.697.1323
Why I believe $BIEL is a good bet Quick summary: They have an actual product PEMF (Pulsed Electro-Magnetic Field) device that you can purchase right now at CVS, Amazon (4/5 stars 522 reviews), Target, Walmart, Walgreens…SOLD in nearly every country in the world! Q3 2021 - 1st profitable quarter in history reported. Unheard of in penny land! A must have for anyone who exercises or works out! My wife, family, friends & I all use them with amazing results! I pulled a calf muscle lifting weights & couldn’t walk. I put a KT Recovery + Wave on it. Within 24 hours I was pain free! Many other time I’ve used it with same results! Truth! About $BIEL Bioelectronics Corp. produces a new, FDA approved, PEMF (pulsed electromagnetic field) device called ActiPatch (Recovery RX). The device has been clinically proven to reduce pain by 50% plus it promotes healing (please see links below). Q1 2021 KT Tape (worn by professional athletes) & DonJoy began marketing this device under their brands. KT markets their device under KT recovery + Wave. DonJoy (known for their orthopedic braces) markets a knee wrap with a replaceable Recovery Rx device inside the brace. Recovery Rx is marketed by KT Tape under ‘KT Recovery + Wave’ (retail cost $35 for 250 hours). Available at CVS, Target, Amazon, Walmart & Walgreens. DonJoy (known for their orthopedic braces) markets a knee wrap with a replaceable Recovery Rx device inside the brace ($64.99). DonJoy sells the replacement device, which is the exact same device KT Tape sells, under ‘DonJoy Advantage EME Replacement’ ($39.99 lasts 720 hours). SAI brands OEM partner $BIEL-Recap of Q3 2021 Progress 1) First Profitable Quarter in BIEL's History - and this was accomplished amidst all of the electronic component shortages and supply chain disruptions that Covid has caused 2) First 9 months Revenue in 2021 saw a 463% increase over 2020 - any stock analyst will tell you that looking at the same Quarter(s) of the previous year is the correct way to judge company growth, this accounts for the seasonal fluctuations most companies have 3) Australian Partner LMT Surgical reports strong demand and efficacy for RecoveryRx - this excellent video showing RecoveryRx in use from Australia, https://www.youtube.com/watch?v=JgpKlwGzGdI 4) Bangladesh Distributor Roll Out was delayed by Covid, now scheduled for Q1 2022 - Bangladesh is one of the world's fastest-growing economies and one of the fastest growing middle-income countries with a population of 163 million 5) Korean Partner is scheduled for a Q2 2022 Roll Out - 51 million potential new customers 6) BIEL is Working on a New Wound Pain Product and is seeking an OEM Partner - Chronic Wound care is a $10 billion market 7) BIEL R&D is Collaborating with Binghamton University to Develop PSWT for Depression and Anxiety - these conditions afflict 16 million in the US, BIEL has had a long relationship with Binghamton, Dr Ken McLeod of Binghamton is a member of the BIEL Medical Advisory board 8) Major Lenders St Johns & IBEX will Continue to Forgo Interest until at Least Q2 2022 - this gives BIEL breathing room to focus on growing the business https://www.bielcorp.com/products/recoveryrx/ https://www.bielcorp.com/products/actipatch/ https://www.donjoyperformance.com/eme-knee-wrap YouTube video explains ActiPatch https://m.youtube.com/watch?v=H5O3qVED6dA
Why I believe $BIEL is a good bet Quick summary: They have an actual product PEMF (Pulsed Electro-Magnetic Field) device that you can purchase right now at CVS, Amazon (4/5 stars 522 reviews), Target, Walmart, Walgreens…SOLD in nearly every country in the world! Q3 2021 - 1st profitable quarter in history reported. Unheard of in penny land! A must have for anyone who exercises or works out! My wife, family, friends & I all use them with amazing results! I pulled a calf muscle lifting weights & couldn’t walk. I put a KT Recovery + Wave on it. Within 24 hours I was pain free! Many other time I’ve used it with same results! Truth! About $BIEL Bioelectronics Corp. produces a new, FDA approved, PEMF (pulsed electromagnetic field) device called ActiPatch (Recovery RX). The device has been clinically proven to reduce pain by 50% plus it promotes healing (please see links below). Q1 2021 KT Tape (worn by professional athletes) & DonJoy began marketing this device under their brands. KT markets their device under KT recovery + Wave. DonJoy (known for their orthopedic braces) markets a knee wrap with a replaceable Recovery Rx device inside the brace. Recovery Rx is marketed by KT Tape under ‘KT Recovery + Wave’ (retail cost $35 for 250 hours). Available at CVS, Target, Amazon, Walmart & Walgreens. DonJoy (known for their orthopedic braces) markets a knee wrap with a replaceable Recovery Rx device inside the brace ($64.99). DonJoy sells the replacement device, which is the exact same device KT Tape sells, under ‘DonJoy Advantage EME Replacement’ ($39.99 lasts 720 hours). SAI brands OEM partner $BIEL-Recap of Q3 2021 Progress 1) First Profitable Quarter in BIEL's History - and this was accomplished amidst all of the electronic component shortages and supply chain disruptions that Covid has caused 2) First 9 months Revenue in 2021 saw a 463% increase over 2020 - any stock analyst will tell you that looking at the same Quarter(s) of the previous year is the correct way to judge company growth, this accounts for the seasonal fluctuations most companies have 3) Australian Partner LMT Surgical reports strong demand and efficacy for RecoveryRx - this excellent video showing RecoveryRx in use from Australia, https://www.youtube.com/watch?v=JgpKlwGzGdI 4) Bangladesh Distributor Roll Out was delayed by Covid, now scheduled for Q1 2022 - Bangladesh is one of the world's fastest-growing economies and one of the fastest growing middle-income countries with a population of 163 million 5) Korean Partner is scheduled for a Q2 2022 Roll Out - 51 million potential new customers 6) BIEL is Working on a New Wound Pain Product and is seeking an OEM Partner - Chronic Wound care is a $10 billion market 7) BIEL R&D is Collaborating with Binghamton University to Develop PSWT for Depression and Anxiety - these conditions afflict 16 million in the US, BIEL has had a long relationship with Binghamton, Dr Ken McLeod of Binghamton is a member of the BIEL Medical Advisory board 8) Major Lenders St Johns & IBEX will Continue to Forgo Interest until at Least Q2 2022 - this gives BIEL breathing room to focus on growing the business https://www.bielcorp.com/products/recoveryrx/ https://www.bielcorp.com/products/actipatch/ https://www.donjoyperformance.com/eme-knee-wrap YouTube video explains ActiPatch https://m.youtube.com/watch?v=H5O3qVED6dA Do your own DD and never risk what you can not afford to lose! GLTU
I believe BIEL (Bioelectronics Corp.) is going to see huge pps increase within 2022. Never invest solely based on someone’s “tip” but I’d certainly check it out. Do some reading on the technology and decide for yourself. DD is key. GL
BIEL is a hot tech stock to own right now, imo, they make a wearable EMP devices that reduces pain. The Bioelectronics Corporation is their name and their stock price is very inexpensive right now.
I agree been following BIEL a long time. All the new moves they have done in the past couple years will put them where hopefully everyone can see and use there PEMF products
BIEL will probably RUN UP BIG like last February 2021. WHY? For Starters They were profitable this last 3rd quarter and most likely they are more profitable for the4th quarter of 2021 when they make that announcement it in February 2022. Also TOO MENTION, They have a very cool product thats wearable and diminishes Pain without the use of drugs, its an electromagnetic pulse frequency device that has 5 FDA Approvals. Also they partnered with KT Tape who are selling and marketing their products in North America, Europe and Abroad. This product is available at CVS stores, Amazon, and Soon Target stores. The product is called KT Recovery Wave (Marketed under Actipatch worldwide) Biel is a hidden GEM that is way undervalued at this point of time.
BIEL - KT Recovery is awesome. Expanded distr to UK recently w/ success & other countries coming too. Agree on set up. Profitable as a $.0010 stock. Was $.0036 range around summer olympics. Winter Olympics will provide similar if not more escalation due to distrib expansion successes. Love CEO.
I have BIEL this company is setting themselves up for huge gains, just became profitable! Not your usual penny stock.
BIEL had a positive q3. Now let’s see this rise 😀
https://www.youtube.com/watch?v=diYS8jyOcFc #I DON'T WANNA KNOW #WHO'S SUCKIN MY COCK TONIGHT #I'M GOIN' TO THE GLORY HOLE #GONNA FUCK IT WITH ALL MY MIGHT #IN MY HEAD IT'S JESSICA BIEL #DON'T CARE IF IT'S A FUCKIN TROLL #GONNA BLOW MY LOAD AT THE GLORY HOLE
GTEH, CBDD, BIEL, GBHL, OXSQ My current long term pennys